Search research articles
Contact Us
Filters
Showing results (221-230 of 233) with videos related to
Page
of 24
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 2, 2014
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
N P Tobin, J C Harrell, J Lövrot, et al.
Lancet (London, England)
|
October 29, 2000
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
J Bergh, T Wiklund, B Erikstein, et al.
Breast Cancer Research and Treatment
|
November 19, 2011
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
T Hatschek, L Carlsson, Z Einbeigi, et al.
Oncogene
|
October 31, 1998
Homozygous deletions at 3p12 in breast and lung cancer
V Sundaresan, G Chung, A Heppell-Parton, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 17, 2018
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
H Lindman, M Andersson, J Ahlgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
H Bonnefoi, S Litière, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
L Pusztai, C Denkert, J O'Shaughnessy, et al.
ESMO Open
|
March 13, 2021
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
A Matikas, K Wang, E Lagoudaki, et al.
British Journal of Cancer
|
March 2, 2013
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study
S Walters, C Maringe, J Butler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, R E Coleman, C Wilson, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 233) with videos related to
Sort By:
Page
of 24
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 2, 2014
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
N P Tobin, J C Harrell, J Lövrot, et al.
Lancet (London, England)
|
October 29, 2000
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
J Bergh, T Wiklund, B Erikstein, et al.
Breast Cancer Research and Treatment
|
November 19, 2011
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
T Hatschek, L Carlsson, Z Einbeigi, et al.
Oncogene
|
October 31, 1998
Homozygous deletions at 3p12 in breast and lung cancer
V Sundaresan, G Chung, A Heppell-Parton, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 17, 2018
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
H Lindman, M Andersson, J Ahlgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
H Bonnefoi, S Litière, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
L Pusztai, C Denkert, J O'Shaughnessy, et al.
ESMO Open
|
March 13, 2021
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
A Matikas, K Wang, E Lagoudaki, et al.
British Journal of Cancer
|
March 2, 2013
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study
S Walters, C Maringe, J Butler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, R E Coleman, C Wilson, et al.
Page
of 24